IPF 2009 - Management of castrate resistant prostate cancer - Session Highlights
Monday, 26 October 2009
IZMIR, TURKEY (UroToday.com) -
Castrate resistant prostate cancer (CRPC) is still sensitive to androgen therapy and the addition of androgens will increase the growth rate of CRPC.
Login to read more...
|
IPF 2009 - Approach to local failure after radiation therapy - Session Highlights
Monday, 26 October 2009
IZMIR, TURKEY (UroToday.com) -
The PSA level after external beam radiation therapy should be low (< 1ng/ml), but there is no clear nadir PSA that is predictive of response.
Login to read more...
|
IPF 2009 - How to handle side effects of hormone therapy (HT) in prostate cancer - Session Highlights
Monday, 26 October 2009
IZMIR, TURKEY (UroToday.com) - The three major side effects of HT in prostate cancer are loss of libido, erectile dysfunction, and metabolic syndrome.
Login to read more...
|
IPF 2009 - Treatment of metastatic prostate cancer: New strategies - Session Highlights
Monday, 26 October 2009
IZMIR, TURKEY (UroToday.com) -
Provenge has been shown to improve the survival of men with castrate resistant prostate cancer (CRPC).
Login to read more...
|
IPF 2009 - Quality of life after primary treatment of prostate cancer - Session Highlights
Monday, 26 October 2009
IZMIR, TURKEY (UroToday.com) - Long-term cure is expected after radical prostatectomy for clinically localized prostate cancer, thus concentration on improving the quality of life after treatment is critical.
Login to read more...
|
IPF 2009 - Intrapelvic venous congestion syndrome - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Chronic prostatitis has been used to describe many pelvic pain syndromes.
Login to read more...
|
IPF 2009 - What has changed in our understanding of BPH? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) -
Progression of BPH is defined as worsening of AUA-SS of >4 points or urinary retention.
Login to read more...
|
IPF 2009 - How and why to manage BPH - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) -
Renal and bladder preservation are the main reasons to treat BPH symptoms.
Login to read more...
|
IPF 2009 - Molecular markers in prostate cancer - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Androgen receptor is critical for prostate cancer formation.
Login to read more...
|
IPF 2009 - What is new with PSA? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - PSA is a biomarker for future prostate cancer risk.
Login to read more...
|
IPF 2009 - Is there a better grading system than Gleason score? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Reports from the International Society of Urologic Pathologists (ISUP) conference indicate that Gleason score is the best prognostic factor in prostate cancer and that there is a poor correlation with radical prostatectomy specimen.
Login to read more...
|
IPF 2009 - Do we need new markers in prostate cancer? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - YES, new markers are critically needed to better detect prostate cancer.
Login to read more...
|
IPF 2009 - Prostate biopsy techniques - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - For prostate biopsy, the extended 12-core technique is the standard of care.
Login to read more...
|
IPF 2009 - What should the pathologist provide in the biopsy report? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - In the prostate cancer biopsy report, it is better to reflect individual cores, rather than multiple cores lumped together.
Login to read more...
|
IPF 2009 - New imaging methods in prostate cancer - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Elastography is a software program that translates how elastic the prostate is, and thus the risk of cancer.
Login to read more...
|
IPF 2009 - Organ confined prostate cancer: To treat or not to treat? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - There is a need to treat organ confined prostate cancer because under-staging of prostate cancer is a persistent problem.
Login to read more...
|
IPF 2009 - How to identify patients for active surveillance - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Overall, short-term outcomes of active surveillance (AS) are similar to active treatment, but greatly influenced by patient selection.
Login to read more...
|
IPF 2009 - Robotic-assisted radical prostatectomy - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) -
Key moves:
Endopelvic fascia – Remove fat from the prostate.
Login to read more...
|
IPF 2009 - Prostate brachytherapy in the 21st century - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Brachytherapy is high dose, highly conformal radiation therapy.
Login to read more...
|
IPF 2009 - Optimal treatment of locally advanced prostate cancer - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Radiation therapy may inadequately eliminate the primary prostate cancer.
Login to read more...
|
IPF 2009 - Focal therapy of the prostate - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) -
It is recommended to perform saturation biopsies, rather than relying on a 12-core biopsy, to determine if a patient is candidate for focal therapy.
Login to read more...
|
IPF 2009 - Immediate or adjuvant radiation therapy after radical prostatectomy - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Positive surgical margins occur in 11-38% of radical prostatectomy specimens.
Login to read more...
|
IPF 2009 - Prostate cancer prevention: Are we there yet? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Finasteride reduces the risk of prostate cancer with a 25% relative risk reduction in the PCPT trial.
Login to read more...
|
IPF 2009 - Soy isoflavones in conjunction with cancer chemotherapy and radiation - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) -
Soy is a selective estrogen receptor modulator and may exert anti-tumor effects via this mechanism.
Login to read more...
|
IPF 2009 - Handling potency and lengthening penis after radical prostatectomy - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) -
Radical prostatectomy can cause hypoxia of the penis and neuropraxia of the neurovascular bundle.
Login to read more...
|
Conference Coverage 
